New Insight: A Look at OPT-302/Sozinibercept with Megan Baldwin, PhD

Host Veeral Sheth, MD is joined by Megan Baldwin, PhD, CEO and Managing Director of Opthea Limited, to discuss OPT-302 or sozinibercept, the company's novel anti-VEGF-C / VEGF-D treatment for wet AMD and other retinal diseases.

Please direct any podcast-related inquiries to ciapoce@mjhlifesciences.com.